Form 4: United Therapeutics' President and COO, Michael Benkowitz, Executes Stock Options and Sells Shares Under 10b5-1 Plan

Michael Benkowitz, President and COO of United Therapeutics, exercised stock options and sold shares of common stock on March 3, 2025, according to a pre-arranged Rule 10b5-1 trading plan.

Summary

• On March 3, 2025, Michael Benkowitz, the President and COO of United Therapeutics, exercised stock options and sold shares of the company's common stock.
• These transactions were executed under a Rule 10b5-1 trading plan established on August 7, 2024.
• The sales were conducted at various prices, ranging from approximately $308.22 to $318.965 per share.
• A total of 9,679 options were exercised at a price of $111.
• The shares are held in trusts beneficially owned by Benkowitz and his family members.
• Following the reported transactions, Benkowitz directly owns 2,577 shares of common stock and indirectly owns shares through trusts.

Sentiment

Score: 5

Explanation: This is a neutral disclosure of insider trading activity under a pre-arranged plan. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

This filing is a routine disclosure of insider transactions and is common for executives who have stock options as part of their compensation. The use of a 10b5-1 plan indicates that the transactions were pre-planned and not based on any inside information at the time of the trades.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the increased supply of shares in the market.
• The transactions do not appear to have any direct impact on employees, customers, suppliers, or creditors.

Key Dates